Image Place holder

Kedar Kirtane, MD

Specialty: Medical Oncology
Program: Head and Neck Oncology


Cancer Focus: Adrenal Carcinoma, Head and Neck Cancer, Thyroid Cancer

Dr. Kirtane is an  Assistant Member at Moffitt Cancer Center in the Department of Head and Neck-Endocrine Oncology. Dr. Kirtane received his MD degree from The University of Florida College of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center. Dr. Kirtane completed a Hematology/Oncology Fellowship at the University of Washington and a Post-Doctoral Fellowship in Oncology at Fred Hutchinson Cancer Research Center. His clinical focus is patients with head and neck-endocrine cancers. He is interested in working with the Department of Health Outcomes and Behavior and the Department of Cancer Epidemiology to help increase access to cancer care for racial/ethnic minorities with cancer. Dr. Kirtane's research interests also include the development of innovative cellular therapies for solid tumor malignancies.

Education & Training

Board Certification:

  • Internal Medicine


  • University of Washington - Hematology/Oncology
  • Fred Hutchinson Cancer Research Center - Oncology


  • Duke University - Internal Medicine

Medical School:

  • University of Florida - MD
Participating Trials

Assessing Distress in Family Caregivers of Patients Receiving Cellular Therapies
Condition: Immunotherapy

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Tan E, Gakhar N, Kirtane K. TCR gene-engineered cell therapy for solid tumors. Best Pract Res Clin Haematol. 2021 Sep.34(3):101285. Pubmedid: 34625228.
  • Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel). 2021 Mar.13(5). Pubmedid: 33803335. Pmcid: PMC7967147.
  • Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33477635. Pmcid: PMC7831487.
  • Naffouje SA, Sabesan A, Hallanger-Johnson J, Kirtane K, Gonzalez RJ, Mullinax J. Adrenal biopsy, as a diagnostic method, is associated with decreased overall survival in patients with T1/T2 adrenocortical carcinoma: A propensity score-matched analysis. J Surg Oncol. 2021 Aug. Pubmedid: 34424540.
  • Reckamp KL, Patil T, Kirtane K, Rich TA, Espenschied CR, Weipert CM, Raymond VM, Santana-Davila R, Doebele RC, Baik CS. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clin Lung Cancer. 2020 Nov.21(6):545-552.e1. Pubmedid: 32665165.
  • Kirtane K, Roth MY. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer. CURR TREAT OPTION ON. 2020 Feb.21(3):18. Pubmedid: 32048061.
  • Loggers ET, Kirtane K, Palacios R, Lewis F. Leaving footprints, not scars: a qualitative pilot study of Hispanic mothers' willingness to communicate with dependent children about an advanced cancer diagnosis. Support Care Cancer. 2019 Apr.27(4):1573-1578. Pubmedid: 30719659.
  • Kirtane K, Downey L, Lee SJ, Curtis JR, Engelberg RA. Intensity of End-of-Life Care for Patients with Hematologic Malignancies and the Role of Race/Ethnicity. J Palliat Med. 2018 Oct.21(10):1466-1471. Pubmedid: 29975599. Pmcid: PMC6201780.
  • Buckley SA, Kirtane K, Walter RB, Lee SJ, Lyman GH. Patient-reported outcomes in acute myeloid leukemia: Where are we now?. Blood Rev. 2018 Jan.32(1):81-87. Pubmedid: 28888621.
  • Kirtane K, Rodriguez CP. Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC). Front Oncol. 2018 Dec.8:588. Pubmedid: 30564559. Pmcid: PMC6288294.
  • Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood. 2017 Oct.130(15):1699-1705. Pubmedid: 28724539. Pmcid: PMC5639484.


Title: Assessing distress in family caregivers of patients receiving cellular therapies: a mixed-methods needs assessment
Sponsor: Nat Institutes of Health
PI: Kirtane, K.

Patient Comments
Overall Satisfaction

75 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments